Medication Brand Names Beginning with ‘X’, Page 5

Page 5 of 28 « First Page « … 3 4 5 6 7 … 10 15 20 25 … » Last Page »

Xartemis XR (Oxycodone Hydrochloride and Acetaminophen)

XARTEMIS XR is indicated for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. Limitations of Use. Because of the risks of addiction, abuse, and misuse with opioids,…

Mallinckrodt, Inc12 September 2017

Xartemis XR (Oxycodone Hydrochloride and Acetaminophen)

XARTEMIS XR is indicated for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. Limitations of Use. Because…

PD-Rx Pharmaceuticals, Inc.30 July 2018

Xartemis XR (Oxycodone Hydrochloride and Acetaminophen)

XARTEMIS XR is indicated for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. Limitations of Use. Because…

SpecGx LLC22 August 2018

Xatmep (Methotrexate)

XATMEP is a folate analog metabolic inhibitor indicated for the: Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy…

Silvergate Pharmaceuticals, Inc.5 June 2019

Xatmep (Methotrexate)

XATMEP is a folate analog metabolic inhibitor indicated for the: Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy…

Azurity Pharmaceuticals, Inc.31 March 2020

Page 5 of 28 « First Page « … 3 4 5 6 7 … 10 15 20 25 … » Last Page »

FDA Medwatch

CME America Announces a Follow-Up on the Voluntary Recall of BodyGuard® Infusion System Administration Sets
Tue, 07 Jul 2020. As part of CME America's commitment to quality, following the previously announced recall (April 27, 2020) of the BodyGuard® Infusion Pump Systems, the company conducted additional flow-rate accuracy testing. This testing revealed that some…
Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets, 500mg and 1000mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
Tue, 07 Jul 2020. Lupin Pharmaceuticals Inc. is voluntarily recalling all batches of Metformin Hydrochloride Extended-Release Tablets USP, 500mg and 1000mg to the consumer level. As part of the ongoing assessment and continuation of the dialog with the FDA,…

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.